Please assess the completion status of the following clinical trial:

Trial Title: A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 positive by licensed diagnostic test~2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)~3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for at least 24 weeks~4. No change in antiretroviral therapy within 12 weeks prior to screening~5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater then 500 copies/mL~6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors~7. Able to provide written informed consent~Exclusion Criteria:~1. The following laboratory variables:~   * absolute neutrophil count (ANC) \< 500 cells/microlitres~  * hemoglobin \< 7.0 g/decilitres~  * platelet count \< 50,000 cells/microlitres~  * ALT great than 5 x ULN~2. Pregnant or nursing mothers~3. Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen~4. Use of immunomodulators within 30 days prior to screening~5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)~6. Intercurrent illness requiring hospitalization~7. Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator~8. Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study~9. Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ritonavir-boosted lopinavir and 2N(t)RTI (Type: ACTIVE_COMPARATOR): This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
- Ritonavir-boosted lopinavir and raltegravir (Type: EXPERIMENTAL): This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.

Based on this trial design, predict the completion outcome and termination type (if applicable).